Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry 2008; 165: 221–228[Abstract/Free Full Text]Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 2007; 33: 21–32 Available online at http://schizophreniabulletin.oxfordjournals.org/cgi/content/full/33/1/21
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007; 33: 1120–1130[Abstract/Free Full Text]
Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007; 68: 815–825
Craddock N, O'Donovan MC, Owen MJ. Phenotypic and genetic complexity of psychosis. Invited commentary on... Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 200–203[Abstract/Free Full Text]
Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007; 30: 511–33[Medline]
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA (CATIE Investigators; Neurocognitive Working Group). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633–647[Abstract/Free Full Text]
Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1061–1071[Abstract/Free Full Text]
Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment refractory schizophrenia. Psychiatr Serv 2007; 58: 983–990[Abstract/Free Full Text]
Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007; 20: 138–142[Medline]
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1050–1060[Abstract/Free Full Text]
McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 1791–1802[Abstract/Free Full Text]
Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull 2007; 33: 1093–1099 Available online at http://schizophreniabulletin.oxfordjournals.org/cgi/content/abstract/33/5/1093[Abstract/Free Full Text]
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK (CATIE Investigators). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415–427[Abstract/Free Full Text]
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA (CATIE Investigators). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428–436[Abstract/Free Full Text]
Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007; 33: 69–94[Abstract/Free Full Text]
Weiden PJ, Buckley PF, Grody M. Understanding and treating "first-episode" schizophrenia. Psychiatr Clin North Am 2007; 30: 481–510[Medline]
Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32: 200–202 Available online at http://schizophreniabulletin.oxfordjournals.org/cgi/content/full/32/2/200
Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006; 163: 1697–1704[Free Full Text]
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB (HGDH Study Group). Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006; 86: 234–243[Medline]
Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R (Clozapine and Risperidone Enhancement (CARE) Study Group). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472–482[Abstract/Free Full Text]
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–1087[Abstract/Free Full Text]
Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214–219[Free Full Text]
Marder SR. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J Clin Psychiatry 2006; 67: e03[Medline]
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (CATIE Investigators). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–610[Abstract/Free Full Text]
Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57: 1482–1487[Abstract/Free Full Text]
Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006; 88: 5–25[Medline]
Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480–491[Medline]
Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatr. 2006; 19: 158–164[Medline]
Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679–685[Abstract/Free Full Text]
Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006; 163: 2096–2102[Abstract/Free Full Text]
Shad MU, Tamminga CA, Cullum M, Haas GL, Keshavan MS. Insight and frontal cortical function in schizophrenia: a review. Schizophr Res 2006; 86: 54–70[Medline]
Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006; 188: 510–518[Abstract/Free Full Text]
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (CATIE Investigators). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–622[Abstract/Free Full Text]
Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006; 67: e11[Medline]
Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry 2006; 163: 365–373[Abstract/Free Full Text]
Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441–449[Abstract/Free Full Text]
Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31: 5–19[Abstract/Free Full Text]
Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 2005; 42: 193–204[Abstract/Free Full Text]
Elbogen EB, Swanson JW. Swartz MS, Van Dorn R. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis 2005; 193: 673–679[Medline]
Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich L-A. Pregnancy, delivery and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162: 79–91[Abstract/Free Full Text]
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223[Abstract/Free Full Text]
McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32[Medline]
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1): 1–93[Medline]
Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005; 162: 2220–2232[Abstract/Free Full Text]
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785–1804[Abstract/Free Full Text]
Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (Early Psychosis Global Working Group). Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947–953[Abstract/Free Full Text]
Asarnow JR, Tompson MC, McGrath EP: Annotation: childhood onset schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry 2004; 45: 180–194[Medline]
Correll CU, Leucht S, Kane JM. Lower risk of tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–425[Abstract/Free Full Text]
Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349[Abstract/Free Full Text]
Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 23( 5 suppl 1): S1–S6
Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 2004; 306: 443–447[Abstract/Free Full Text]
Ridderinkhof KR, van den Wildenberg WP, Segalowitz SJ, Carter CS. Neurocognitive mechanisms of cognitive control: the role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn 2004; 56: 129–140[Medline]
Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 473–479[Abstract/Free Full Text]
Vauth R, Loschmann C, Rusch N, Corrigan PW. Understanding adherence to neuroleptic treatment in schizophrenia. Psychiatry Res 2004; 126: 43–49[Medline]
Hyman SE, Fenton WS. Medicine: what are the right targets for psychopharmacology? Science 2003; 299: 350–351[Abstract/Free Full Text]
Palmer BW, McClure FS, Jeste DV: Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry 2001; 9: 51–58[Medline]
Howard P, Rabins PV, Seeman MV, Jeste DP (International Late-Onset Schizophrenia Group): Late-onset schizophrenia and very late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry 2000; 157: 172–178[Abstract/Free Full Text]
Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20: 106–118[Medline]
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–330[Abstract/Free Full Text]
Liddle PF. The symptoms of chronic schizophrenia: A re-examination of the positive and negative dichotomy. Br J Psychiatry 1987; 151: 145–151[Abstract/Free Full Text]
TOP
ABSTRACT
REFERENCES
